Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
516.69
-3.40 (-0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
517.50
+0.81 (0.16%)
After-hours: Apr 28, 2026, 7:37 PM EDT
Company Description
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 915 |
| CEO | William Sibold |
Contact Details
Address: Four Tower Bridge, 200 Barr Harbor Drive West Conshohocken, Pennsylvania 19428 United States | |
| Phone | 267 824 2827 |
| Website | madrigalpharma.com |
Stock Details
| Ticker Symbol | MDGL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001157601 |
| CUSIP Number | 558868105 |
| ISIN Number | US5588681057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Sibold | Chief Executive Officer, President and Director |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific and Medical Advisor and Director |
| Mardi C. Dier | Executive Vice President and Chief Financial Officer |
| Shannon Kelley | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer |
| Mark Underwood | Executive Vice President of Business Planning and Operations |
| Rita Thakkar | Senior Vice President and Chief Accounting Officer |
| Ronald Filippo | Executive Vice President and Chief Information Officer |
| Tina E. Ventura | Chief Investor Relations Officer |
| Clint Wallace | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |